Protara Therapeutics (1KPA) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1KPA Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Protara

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1KPA Stock 12 Month Forecast

Average Price Target

€22.80

▲(449.30% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Protara Therapeutics in the last 3 months. The average price target is €22.80 with a high forecast of €24.55 and a low forecast of €21.04. The average price target represents a 449.30% change from the last price of €4.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","7":"€7","13":"€13","19":"€19","25":"€25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24.54927972,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€24.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.79575974,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€22.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.04223976,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7,13,19,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.14,4.786867670769231,6.433735341538462,8.080603012307693,9.727470683076923,11.374338353846156,13.021206024615386,14.668073695384617,16.314941366153846,17.96180903692308,19.60867670769231,21.25554437846154,22.902412049230772,{"y":24.54927972,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.14,4.651981518461539,6.163963036923077,7.675944555384616,9.187926073846155,10.699907592307694,12.211889110769231,13.72387062923077,15.23585214769231,16.74783366615385,18.259815184615388,19.771796703076927,21.283778221538462,{"y":22.79575974,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.14,4.517095366153846,5.894190732307692,7.271286098461539,8.648381464615385,10.02547683076923,11.402572196923078,12.779667563076924,14.15676292923077,15.533858295384615,16.91095366153846,18.288049027692306,19.665144393846155,{"y":21.04223976,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.44,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.216,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.812,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€24.55

Average Price Target€22.80

Lowest Price Target€21.04

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

06/30/26

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Illumina (NASDAQ: ILMN) and Protara Therapeutics (NASDAQ: TARA)

Andres Y. Maldonado

H.C. Wainwright

€23.67

Buy

470.42%

Upside

Reiterated

05/20/26

Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Elevance Health (ELV)

Kelsey Goodwin

Piper Sandler

€21.04

Buy

407.04%

Upside

Reiterated

05/20/26

Analysts Offer Insights on Healthcare Companies: Traws Pharma (NASDAQ: TRAW) and Protara Therapeutics (NASDAQ: TARA)

Charles Zhu

LifeSci Capital

€19.29→€22.8

Buy

449.30%

Upside

Reiterated

05/20/26

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (NASDAQ: PEPG) and Protara Therapeutics (NASDAQ: TARA)

Stacy Ku

TD Cowen

―

Buy

―

Assigned

05/20/26

Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (NASDAQ: RANI), Alpha Tau Medical Ltd (NASDAQ: DRTS) and Protara Therapeutics (NASDAQ: TARA)

Leland Gershell

Oppenheimer

€21.92→€24.55

Buy

491.55%

Upside

Reiterated

05/20/26

Protara Therapeutics (TARA) Receives a Buy from Oppenheimer

Boris Peaker

JonesTrading

€21.92

Buy

428.17%

Upside

Reiterated

05/19/26

Peaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

06/30/26

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Illumina (NASDAQ: ILMN) and Protara Therapeutics (NASDAQ: TARA)

Andres Y. Maldonado

H.C. Wainwright

€23.67

Buy

470.42%

Upside

Reiterated

05/20/26

Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Elevance Health (ELV)

Kelsey Goodwin

Piper Sandler

€21.04

Buy

407.04%

Upside

Reiterated

05/20/26

Analysts Offer Insights on Healthcare Companies: Traws Pharma (NASDAQ: TRAW) and Protara Therapeutics (NASDAQ: TARA)

Charles Zhu

LifeSci Capital

€19.29→€22.8

Buy

449.30%

Upside

Reiterated

05/20/26

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (NASDAQ: PEPG) and Protara Therapeutics (NASDAQ: TARA)

Stacy Ku

TD Cowen

―

Buy

―

Assigned

05/20/26

Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (NASDAQ: RANI), Alpha Tau Medical Ltd (NASDAQ: DRTS) and Protara Therapeutics (NASDAQ: TARA)

Leland Gershell

Oppenheimer

€21.92→€24.55

Buy

491.55%

Upside

Reiterated

05/20/26

Protara Therapeutics (TARA) Receives a Buy from Oppenheimer

Boris Peaker

JonesTrading

€21.92

Buy

428.17%

Upside

Reiterated

05/19/26

Peaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Protara Therapeutics

3 Months

Leland GershellOppenheimer

Success Rate

8/18 ratings generated profit

Average Return

+24.09%

Copying Leland Gershell's trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +24.09% per trade.

1 Year

Stacy KuTD Cowen

Success Rate

6/13 ratings generated profit

Average Return

+2.83%

Copying Stacy Ku's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +2.83% per trade.

2 Years

Leland GershellOppenheimer

Success Rate

9/18 ratings generated profit

Average Return

+45.33%

Copying Leland Gershell's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +45.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1KPA Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1KPA has received 15 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1KPA average Analyst price target in the past 3 months is 22.80.

Each month's total comprises the sum of three months' worth of ratings.

1KPA Financial Forecast

1KPA Earnings Forecast

Next quarter’s earnings estimate for 1KPA is -€0.29 with a range of -€0.31 to -€0.27. The previous quarter’s EPS was -€0.27. 1KPA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 1KPA has Performed in-line its overall industry.

No data currently available

1KPA Sales Forecast

Next quarter’s sales forecast for 1KPA is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 1KPA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 1KPA has Performed in-line its overall industry.

1KPA Stock Forecast FAQ

What is DE:1KPA’s average 12-month price target, according to analysts?

Based on analyst ratings, Protara Therapeutics, Inc.’s 12-month average price target is 22.80.

What is DE:1KPA’s upside potential, based on the analysts’ average price target?

Protara Therapeutics, Inc. has 449.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Protara Therapeutics, Inc. a Buy, Sell or Hold?

Protara Therapeutics, Inc. has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Protara Therapeutics, Inc.’s share price target?

The average share price target for Protara Therapeutics, Inc. is 22.80. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €24.55 ,and the lowest forecast is €21.04. The average share price target represents 449.30% Increase from the current price of €4.15.

What do analysts say about Protara Therapeutics, Inc.?

Protara Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Protara Therapeutics, Inc.?

To buy shares of DE:1KPA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Protara Therapeutics (1KPA) Stock Forecast & Price Target

1KPA Analyst Ratings

1KPA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Protara Therapeutics

1KPA Analyst Recommendation Trends

1KPA Financial Forecast

1KPA Earnings Forecast

1KPA Sales Forecast

1KPA Stock Forecast FAQ

Detailed List of Analyst Forecasts